GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company working in gene expression control. Its stock price represents a venture bet on its scientific platform. The chart reflects high volatility and dependence on clinical trial data.
Share prices of companies in the market segment - Dna
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of cancer and rare genetic diseases. We've classified it as a "DNA" company. The chart below shows how the market views the prospects for epigenetic medicine.
Broad Market Index - GURU.Markets
Syros Pharmaceuticals is a biotech company developing gene-modulating drugs for the treatment of cancer and rare genetic diseases. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Syros's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
SYRS - Daily change in the company's share price Syros Pharmaceuticals
For Syros Pharmaceuticals, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Dna
Syros Pharmaceuticals develops drugs that target gene expression for the treatment of cancer. This is a cutting-edge and risky area of biotechnology. The chart below illustrates the high volatility typical of this sector, reflecting the stakes associated with SYRS's clinical trials.
Daily change in the price of a broad market stock, index - GURU.Markets
Syros Pharmaceuticals is a biotech company developing drugs that regulate gene expression. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamics of the innovation sector, which influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Syros Pharmaceuticals
Syros Pharmaceuticals' year-to-date performance is a story about the development of its gene-regulating drugs. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate for the treatment of blood cancer could be a breakthrough and a validation of its unique scientific platform.
Annual dynamics of market capitalization of the market segment - Dna
Syros, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its gene-modifying platform. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Syros Pharmaceuticals is a biotech company whose value is locked into its RNA platform. Its shares move with clinical trial news, not economic cycles. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Syros Pharmaceuticals
Syros is a late-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its key clinical trials. Data on its blood cancer treatments is the key event shaping expectations.
Monthly dynamics of market capitalization of the market segment - Dna
Syros Pharmaceuticals is a biotech company specializing in the development of drugs that control gene expression. This approach can be applied to the treatment of various types of cancer. The graph below illustrates the dynamics of the biotech sector, where innovative approaches to gene regulation are at the forefront of science.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression. This is cutting-edge science. The company's shares are driven by news of clinical trials, and their performance is completely disconnected from overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Syros Pharmaceuticals
Syros, a biotech company focused on regulating gene expression, is a reflection of the future of blood cancer treatment. Its stock price is responding to clinical trial data that could confirm the potential of its approach to turning on and off disease-causing genes.
Weekly dynamics of market capitalization of the market segment - Dna
Syros Pharmaceuticals develops gene-modulating drugs for the treatment of cancer and rare diseases. This chart compares its volatile, news-driven performance with the biotech sector and helps us understand the investor confidence in its innovative scientific platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Syros Pharmaceuticals is a biotech company working in the cutting-edge field of gene therapy. Shares of such innovative companies often move independently of the market. This chart will help you understand: does Syros exist in its own world of clinical trials, or does the overall market environment influence its stock price?
Market capitalization of the company, segment and market as a whole
SYRS - Market capitalization of the company Syros Pharmaceuticals
Syros's market capitalization tells the story of a biotech company focused on gene regulation for cancer treatment. Its volatile chart reflects its long journey of research and the recent merger that yielded a leading drug candidate. Its dynamics reflect the market's assessment of the company's chances of success in late-stage clinical trials.
SYRS - Share of the company's market capitalization Syros Pharmaceuticals within the market segment - Dna
Syros Pharmaceuticals is a biotech company focused on gene regulation for cancer treatment. Its share of the sector's market capitalization reflects investors' faith in its scientific approach. The chart shows how its weighting changes based on news about its drug clinical trials.
Market capitalization of the market segment - Dna
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of cancer. The chart below shows the market capitalization of this cutting-edge sector. Its dynamics reflect the hope that this new treatment approach will help patients who have been unsuccessful with existing treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Syros Pharmaceuticals is a biotech company attempting to manipulate gene expression to treat cancer and genetic diseases. Its market cap reflects its bet on fundamental science. Its volatility on the overall chart reflects how the market views the potential of new ways to control our genes.
Book value capitalization of the company, segment and market as a whole
SYRS - Book value capitalization of the company Syros Pharmaceuticals
Syros Pharmaceuticals' balance sheet consists of its capital and patents for a gene expression control platform aimed at developing drugs for the treatment of blood cancer and other diseases. This is the tangible, scientific foundation for a new approach to targeted therapy. How has this innovative biotech asset changed? The chart below shows its dynamics.
SYRS - Share of the company's book capitalization Syros Pharmaceuticals within the market segment - Dna
Syros Pharmaceuticals develops drugs that regulate gene expression, which requires advanced R&D laboratories. The graph shows the share of these science-intensive tangible assets, reflecting the physical foundation of its innovation platform.
Market segment balance sheet capitalization - Dna
Syros, a development-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Syros's balance sheet is its cutting-edge scientific platform for controlling gene expression to create a new class of drugs for the treatment of cancer and genetic diseases. The company's assets represent its intellectual capital. The chart below shows how this pioneer in gene regulation stacks up in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Syros Pharmaceuticals
Syros Pharmaceuticals works in the field of gene regulation to create new drugs. Its balance sheet is its scientific platform. Its market capitalization reflects investors' bets that its approach will lead to breakthroughs in the treatment of cancer and other diseases. The chart reflects the hopes placed on this cutting-edge science.
Market to book capitalization ratio in a market segment - Dna
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of oncology and genetic diseases. Its valuation on the chart is based on the potential of its innovative scientific platform.
Market to book capitalization ratio for the market as a whole
Syros Pharmaceuticals works in the field of gene modulation for disease treatment. Its value is derived almost entirely from intangible assets—its scientific platform and patents. The chart helps assess the premium for breakthrough but risky scientific approaches compared to the market average.
Debts of the company, segment and market as a whole
SYRS - Company debts Syros Pharmaceuticals
Syros Pharmaceuticals, a late-stage biotech developing drugs to treat blood cancer, is using capital to fund its crucial clinical trials. This chart shows how the company is raising significant funds to take the final step toward potentially bringing its new treatment to market.
Market segment debts - Dna
Syros Pharmaceuticals is a late-stage biotech company developing drugs to control gene expression. This chart shows that the company, like its peers, funds its expensive final-stage research primarily with equity capital to bring its drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company working in the cutting-edge field of gene expression control for cancer treatment. Its success depends on the results of clinical trials. This chart shows how much the company relies on debt to finance its expensive research, a direct measure of its financial risk.
Market segment debt to market segment book capitalization - Dna
Syros Pharmaceuticals works in the cutting-edge field of gene regulation, developing drugs that control the "switching on" and "switching off" of genes to treat diseases. This chart shows how aggressively the biotech sector uses debt to finance such revolutionary, yet risky, approaches, and how Syros compares against this backdrop.
Debt to book value of all companies in the market
Syros Pharmaceuticals, a pioneer in gene expression control, operates at the cutting edge of science, requiring massive and risky investments in R&D. This chart, reflecting the overall market debt burden, allows one to assess the company's financial model. It shows how Syros finances its fundamental research without stable revenues.
P/E of the company, segment and market as a whole
P/E - Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of oncology and monogenic diseases. This chart shows how the market values its cutting-edge scientific platform. This assessment is based on the potential of its approach to creating a new class of drugs.
P/E of the market segment - Dna
Here's the average P/E for biotech companies. For Syros Pharmaceuticals, which works in gene regulation, it serves as a benchmark. It reflects the overall level of optimism in the sector. This provides context for Syros's valuation, which is a bet that its scientific platform will lead to the development of new drugs.
P/E of the market as a whole
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. Syros's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Syros Pharmaceuticals
For Syros Pharmaceuticals, Inc., a company developing drugs that control gene expression, this chart shows market expectations for its clinical programs. It reflects investor confidence in the potential of its innovative platform for treating blood cancers and solid tumors.
%20P%2FE%20Syros%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Syros-Pharmaceuticals&v=1772612596434 "Chart of the company's future (projected) P/E Syros Pharmaceuticals")
Future (projected) P/E of the market segment - Dna
Syros Pharmaceuticals is a biopharmaceutical company focused on gene expression control to develop treatments for blood cancers and solid tumors. This is a cutting-edge approach in genetic medicine. The chart shows forecasts for the biotech sector, allowing for a comparison of how the market values Syros's innovative, yet risky, scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772612596460 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Syros Pharmaceuticals, Inc. is a biotech company working in the field of gene expression control for cancer treatment. This is fundamental science. The company's valuation reflects its belief in its scientific platform. This chart shows the market's willingness to invest in science-intensive platform companies with long-term potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612596542 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Syros Pharmaceuticals
Syros Pharmaceuticals is a biopharmaceutical company developing drugs that control gene expression for the treatment of cancer and rare diseases. While in the clinical stage, it is losing money. This chart illustrates the financial implications of cutting-edge research aimed at creating a new class of drugs.
Profit of companies in the market segment - Dna
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression to treat blood cancers and other diseases. This graph, which reflects the sector's profitability, demonstrates how science is seeking new treatment approaches. Their platform enables them to target genes previously considered drug-resistant, opening new therapeutic horizons.
Overall market profit
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of cancer and rare diseases. It is a cutting-edge scientific platform. Funding for such innovative, yet risky, research depends on investor appetite, which typically rises during periods of rising corporate profits.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of blood cancers and solid tumors. This chart represents analyst expectations for the success of this innovative approach and progress in clinical trials, betting on a new paradigm in cancer treatment.
%20profit%20of%20the%20company%20Syros%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Syros-Pharmaceuticals&v=1772612596651 "Graph of future (projected) profit of the company Syros Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Dna
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of cancer and rare diseases. The company's value lies in its gene control platform. This biotech chart reflects the overall investor confidence in the potential of epigenetic medicine and new approaches to treating complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772612596686 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Syros Pharmaceuticals is a pioneer in gene regulation for drug discovery. This cutting-edge science requires significant investment. This graph, reflecting general economic expectations, influences investor willingness to invest in long-term, high-risk biotech platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612596721 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of cancer and rare diseases. Despite the lack of revenue, this chart is crucial. It shows how investors view its innovative scientific platform and the enormous potential for future revenue from its developments.
P/S market segment - Dna
Syros Pharmaceuticals is developing a new class of drugs aimed at controlling gene expression for the treatment of cancer and monogenic diseases. The company's valuation is based on the potential of its unique scientific platform. This chart, which reflects the average valuation in the biotech industry, helps us understand how expectations for Syros's innovative technology align with industry trends.
P/S of the market as a whole
Syros Pharmaceuticals is a biotech company developing gene expression-modulating drugs for the treatment of cancer and monogenic diseases. This chart, which reflects revenue estimates for real businesses, highlights that Syros's valuation is a bet on its innovative scientific platform, which could unlock new treatment approaches.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Syros Pharmaceuticals
Syros Pharmaceuticals is a clinical-stage biotech company focused on developing drugs that control gene expression for the treatment of cancer and rare diseases. This chart reflects investor hopes that its innovative approach to gene regulation will lead to the development of a new class of drugs.
%20P%2FS%20Syros%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Syros-Pharmaceuticals&v=1772612596863 "The graph of the company's future (projected) P/S Syros Pharmaceuticals")
Future (projected) P/S of the market segment - Dna
Syros Pharmaceuticals, Inc. is a late-stage clinical development biopharmaceutical company pioneering the understanding and control of gene expression to create new drugs. This chart shows the average estimated future sales in the biotech sector. It helps understand how highly the market values Syros's scientific platform.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772612596901 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Syros Pharmaceuticals is a biotech company developing gene expression-modulating drugs for the treatment of cancer and genetic diseases. This chart illustrates general market expectations. The company's innovative approach could unlock new ways to combat diseases at a fundamental level, fueling investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612596915 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Syros Pharmaceuticals
This chart shows the revenue of Syros Pharmaceuticals, a clinical-stage biopharmaceutical company developing gene-modulating drugs for the treatment of cancer and rare diseases. Its revenue is generated through collaboration fees with pharmaceutical partners, reflecting research progress.
Sales of companies in the market segment - Dna
Syros Pharmaceuticals is a biotech company developing a new class of drugs that control gene expression for the treatment of cancer and monogenic diseases. This chart illustrates the growth of the gene medicine market. Syros's innovative approach could lead to the creation of therapies for diseases previously considered incurable, expanding the boundaries of pharmaceuticals.
Overall market sales
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression. Its value is based on the potential of its scientific platform. The overall economic situation, reflected in this chart, influences investor willingness to fund fundamental and long-term research in genetics.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of cancer and monogenic diseases. Future revenue depends on the success of its innovative platform. The chart reflects analysts' belief in the potential of gene therapy.
%20sales%20of%20the%20company%20Syros%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Syros-Pharmaceuticals&v=1772612597094 "Schedule of future (projected) sales of the company Syros Pharmaceuticals")
Future (projected) sales of companies in the market segment - Dna
Syros Pharmaceuticals is a biotechnology company pioneering the use of gene expression to create next-generation drugs. Its approach is aimed at treating diseases previously considered untreatable. This chart shows the forecast for the entire gene therapy market, where Syros is at the forefront of science.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772612597155 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of oncology and monogenic diseases. Its valuation is based on the potential of its scientific platform. This graph, reflecting investors' risk appetite, influences the availability of capital for funding innovative approaches in medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612597171 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression to treat cancer and rare diseases. Being in the clinical stage, it incurs significant research expenses. This chart shows its net losses—investments in groundbreaking science that could unlock entirely new ways to treat diseases.
Market segment marginality - Dna
Syros Pharmaceuticals is a late-stage clinical development biopharmaceutical company pioneering the understanding and treatment of diseases by controlling gene expression. Profitability depends on the success of its key programs. This chart reflects the high research costs typical for a company preparing for the potential launch of a new drug.
Market marginality as a whole
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression for the treatment of blood cancers and solid tumors. Their approach is focused on previously inaccessible targets. This overall profitability curve is irrelevant to them. Their future depends solely on the success of their scientific platform and the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression. Its team consists primarily of scientists. The growth in this chart directly reflects the progress of its research platform and the advancement of its candidates into clinical trials.
Share of the company's employees Syros Pharmaceuticals within the market segment - Dna
Syros Pharmaceuticals is a pioneer in gene expression control, developing a new class of drugs that can "turn on" and "turn off" genes. This chart shows the unique scientific talent the company attracts in this cutting-edge field. It is a measure of its scientific potential to create breakthrough treatments.
Number of employees in the market segment - Dna
Syros Pharmaceuticals, Inc. is a late-stage clinical development biopharmaceutical company using its gene expression control platform to create new drugs. This chart shows the employment dynamics in the cutting-edge field of gene medicine. The growing number of scientists here signals progress in clinical trials and the company's approach to market.
Number of employees in the market as a whole
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression. Its advanced platform requires significant investment. Overall economic stability, reflected in this chart, influences investor willingness to fund long-term fundamental research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals is a biotech company working in gene control for cancer treatment. It is a cutting-edge R&D company. The chart shows that the company's market value is a valuation of its scientific platform. The market capitalization per employee here reflects not productivity, but rather investors' faith in the breakthrough potential of their technologies.
%20of%20the%20company%20Syros%20Pharmaceuticals%20(SYRS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Syros-Pharmaceuticals-SYRS&v=1772612597537 "Chart of market capitalization per employee (in thousands of dollars) of the company Syros Pharmaceuticals (SYRS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Syros Pharmaceuticals is a biotech company developing drugs that control gene expression to treat cancer and genetic diseases. Its value is based on its unique scientific platform. This chart demonstrates the high market valuation of its advanced technologies and intellectual property per scientist.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772612597649 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Syros Pharmaceuticals is a biopharmaceutical company developing gene expression-modulating drugs for cancer treatment. The chart illustrates the valuation of their scientific platform. It shows how the market views their innovative treatment approach, which is being developed by a small but highly specialized team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612597677 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals is a clinical-stage biotech company specializing in developing drugs that control gene expression (which genes are turned on or off). This is R&D. This chart shows capital burn: the amount the company spends on each scientist trying to prove the effectiveness of their innovative platform.
%20Chart%20Syros%20Pharmaceuticals%20(SYRS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Syros-Pharmaceuticals-SYRS&v=1772612597785 "Company Profit Per Employee (in thousands of dollars) Chart Syros Pharmaceuticals (SYRS)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Syros Pharmaceuticals is a clinical-stage biotech company specializing in the development of drugs that control gene expression. This is at the cutting edge of science. This metric (loss per employee) reflects the high cost of R&D for this new drug platform.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772612597825 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Syros Pharmaceuticals (SYRS) is a clinical-stage biotech company specializing in the treatment of blood diseases (cancer, sickle cell anemia). It is an R&D company and is not profitable. This chart shows the company's capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612597840 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals is a biotech company focused on developing gene expression-regulating drugs for the treatment of oncology and genetic diseases. This chart reflects the progress of monetizing its scientific platform. Revenue growth at this stage is likely due to partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Syros-Pharmaceuticals-SYRS&v=1772612597861 "Sales chart per company employee Syros Pharmaceuticals (SYRS)")
Sales per employee in the market segment - Dna
Syros Pharmaceuticals (SYRS) is a biotech company focused on a new cancer treatment through gene control (regulation of gene expression). This chart shows how productive their R&D team is. It measures revenue (from partnerships) per scientist, reflecting the value of their scientific platform.
Sales per employee for the market as a whole
Syros Pharmaceuticals (SYRS) is a late-stage biotech company specializing in gene expression-modulating drugs for cancer treatment. The company is preparing for commercialization. This graph illustrates its pre-launch readiness: a large team of specialists is dedicated to R&D and launch preparation, which is an investment in future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals is a biotech company working on gene expression control for cancer treatment. The bearish sentiment shown by this chart is a bet that its cutting-edge, yet highly speculative, scientific platform will fail to produce an effective treatment in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Syros-Pharmaceuticals-SYRS&v=1772612597894 "Short Shares Chart for the Company Syros Pharmaceuticals (SYRS)")
Shares shorted by market segment - Dna
Syros Pharmaceuticals (SYRS) is at the forefront of medicine, developing drugs that control gene expression (genomics). This is a high-tech but speculative field. This chart reflects the total short position volume across the entire genetic engineering sector. It's a "fear" indicator: if it rises, investors fear research setbacks or tightening regulations.
Shares shorted by the overall market
Syros Pharmaceuticals is betting on a breakthrough in gene therapy. This is fundamental science, requiring massive investment. This chart reflects the general fear. When investors are pessimistic, they are unwilling to bet on fundamental R&D. They see SYRS as a cash-burning company and are selling off shares, fearing share dilution or trial failure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals (SYRS) is a biotech company working in gene regulation for the treatment of blood cancers and solid tumors. This fundamental science is at the core of the company. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) on positive early data or "oversold" (below 30) due to capital dilution or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Syros-Pharmaceuticals-SYRS&v=1772612597948 "RSI 14 indicator chart for the company's stock Syros Pharmaceuticals (SYRS)")
RSI 14 Market Segment - Dna
Syros Pharma is a "biotech" and a gene "regulator." Their platform searches for small molecules that control gene expression for the treatment of blood cancer. The RSI_14_Seg index for "Dna" (biotech/oncology) is driven by news. RSI_14_Seg shows the "temperature" of the entire segment. It helps us understand: is SYRS's growth driven by their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Syros Pharmaceuticals (SYRS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SYRS (Syros Pharmaceuticals)
Syros Pharmaceuticals is a biotech company developing gene expression-targeted drugs for the treatment of blood cancers. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of this complex R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SYRS-Syros-Pharmaceuticals&v=1772612597987 "A chart showing analyst consensus forecasts for the expected stock price. SYRS (Syros Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price SYRS (Syros Pharmaceuticals)
Syros (SYRS) is a biotech company that's trying to treat cancer by targeting not the genes themselves, but their *regulation* (reading DNA). This chart shows how far the current share price differs from its "fair" value. It reflects the "venture capital" valuation of analysts for this complex yet cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SYRS-Syros-Pharmaceuticals&v=1772612597994 "A chart showing the difference between the consensus forecast and the actual stock price. SYRS (Syros Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Dna
Syros Pharmaceuticals is a biotech company that attempts to treat cancer by "regulating" genes (rather than attacking proteins). This R&D company is at the cutting edge of science. This chart shows general expectations for the DNA technology sector. It reflects whether experts believe in a breakthrough in gene-based medicine in oncology.
Analysts' consensus forecast for the overall market share price
Syros Pharmaceuticals (SYRS) is a gene "regulator." It's a biotech company that doesn't "fix" DNA, but develops drugs that control the *expression* (switching on/off) of cancer-causing genes. This chart shows the overall risk appetite. It reflects the willingness of investors to fund breakthrough but high-risk R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Syros Pharmaceuticals
Syros Pharmaceuticals is a biotech company focused on controlling gene expression for the treatment of cancer and genetic diseases. This is a cutting-edge, yet risky, field of science. This chart provides a comprehensive barometer of market perception of their scientific platform, the risk of clinical failure, and the financial need to bring their drugs to market.
AKIMA Market Segment Index - Dna
Syros Pharmaceuticals (SYRS) is a DNA biotech. They don't edit genes, but rather aim to control their expression (turn them on and off). Their platform targets blood cancers and rare diseases. This chart compares their composite index to the DNA technology sector average.
The AKIM Index for the overall market
Syros Pharmaceuticals is a biotech company developing treatments for blood cancer (myelodysplastic syndrome) by targeting gene expression. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for evaluating this scientific platform.
